Examkin

Soru

Zorluk: ZorRheumatology and Immunology

A 64-year-old male is brought to the emergency department by his wife due to progressively worsening breathing difficulties over the past ten days. The patient reports a persistent dry cough and states he has been sleeping in a recliner because he feels like he is 'smothering' when lying flat in bed. His medical history is notable for severe, erosive rheumatoid arthritis, hypertension, and moderate chronic obstructive pulmonary disease. Four months prior to this presentation, adalimumab was added to his long-standing regimen of methotrexate and naproxen to achieve better control of his joint disease. He also takes amlodipine and uses a tiotropium inhaler daily.

Temperature is 37.0°C (98.6°F), blood pressure is 156/92 mm Hg, pulse is 108/min, and respirations are 24/min. Pulse oximetry indicates an oxygen saturation of 92% on ambient air. Physical examination reveals jugular venous distension up to 8 cm above the sternal angle. Auscultation of the chest demonstrates a regular tachycardia with a prominent S3 gallop, alongside fine bilateral basilar crackles. No wheezes are appreciated. The lower extremities exhibit 2+ pitting edema extending to the mid-calves.

Laboratory analysis reveals:
- Hemoglobin: 11.2 g/dL
- Leukocyte count: 8,500/mm³
- Thyroid-stimulating hormone: 1.5 µU/mL
- Free thyroxine (T4): 1.3 ng/dL

Arterial blood gas analysis on ambient air:
- pH: 7.48
- PaCO₂: 30 mm Hg
- PaO₂: 64 mm Hg
- HCO₃⁻: 22 mEq/L

Based on the clinical findings, which of the following is the most appropriate next step in the management of this patient?

  1. A
    Administer systemic glucocorticoids and nebulized albuterol
  2. B
    Obtain blood cultures and initiate intravenous piperacillin-tazobactam
  3. Discontinue adalimumab and administer intravenous furosemideCevap
  4. D
    Administer intravenous acetazolamide to correct the acid-base derangement
  5. E
    Discontinue methotrexate and initiate high-dose corticosteroid therapy

Cevap

Discontinue adalimumab and administer intravenous furosemide
The correct answer involves discontinuing the TNF-alpha inhibitor (adalimumab) and initiating diuresis (furosemide). This patient presents with classic signs of acute decompensated heart failure (ADHF), evidenced by orthopnea, jugular venous distension, an S3 gallop, bilateral basilar crackles, and peripheral edema. Adalimumab and other TNF-alpha inhibitors (e.g., infliximab, etanercept) are biologic disease-modifying antirheumatic drugs (DMARDs) associated with a significant risk of precipitating new-onset heart failure or exacerbating pre-existing heart failure. They are absolutely contraindicated in patients with New York Heart Association (NYHA) Class III or IV heart failure. Given the clear signs of volume overload and ADHF occurring relatively soon after the initiation of adalimumab, the offending drug must be stopped immediately, and the pulmonary congestion and peripheral edema should be managed with loop diuretics.

### Clinical Differentiation of Dyspnea in Rheumatoid Arthritis

FeatureAcute Heart Failure (TNF-alpha induced)COPD ExacerbationMethotrexate Pneumonitis
Key SymptomsOrthopnea, PND, progressive dyspneaDyspnea, increased sputum purulenceDry cough, progressive dyspnea
Exam FindingsJVD, S3 gallop, edema, cracklesWheezing, prolonged expirationCrackles, absence of volume overload
Acid-BaseRespiratory alkalosis (early)Respiratory acidosis (often)Respiratory alkalosis
ManagementDiuretics, stop biologic agentBronchodilators, systemic steroidsStop MTX, systemic steroids

Adım Adım Çözüm

1
Analyze the patient's presenting symptoms and physical examination findings.
The patient exhibits orthopnea, jugular venous distension, an S3 gallop, basilar crackles, and bilateral pitting edema.
Identifying this specific constellation of signs and symptoms is necessary to establish that the primary clinical syndrome is acute decompensated heart failure (ADHF) with volume overload.
2
Review the patient's medical history and recent medication changes in the context of the new diagnosis.
The patient was started on adalimumab, a tumor necrosis factor (TNF)-alpha inhibitor, four months prior for severe rheumatoid arthritis.
TNF-alpha inhibitors are a well-documented cause of new-onset or worsening heart failure, making this drug the most likely precipitant of his current ADHF.
3
Determine the most appropriate immediate management for both the acute presentation and the underlying pharmacological cause.
The offending agent (adalimumab) must be discontinued, and the acute volume overload must be treated with a loop diuretic (intravenous furosemide).
Removing the pharmacological trigger and actively diuresing the patient are the fundamental cornerstones of managing drug-induced heart failure exacerbations.

Anahtar Kavram

Tumor necrosis factor (TNF)-alpha inhibitors (e.g., adalimumab, infliximab, etanercept) can precipitate new-onset heart failure or exacerbate pre-existing disease. They are contraindicated in patients with moderate-to-severe heart failure.
Bu soruyu puanla

Konular

Rheumatology and Immunology

Bu konudan daha fazla soru